Image Credit: STAT News
STAT+: Pharmalittle: We’re reading about Novo Nordisk’s cautious culture, FDA approvals, and more
In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused notable weight loss in mice